In the EXCEED study (49), a head-to-head trial, comparing secukinumab (an IL-17 inhibitor) vs. adalimumab (a TNF-α inhibitor) for treatment of active psoriatic arthritis, reported two MACEs in the secukinumab group (n=426) and none in the adalimumab group(n=427). This evidence concerns the gene TNF and psoriatic arthritis.